ONCOLOGY Staff

Read this to learn 3 things you should know about the first-line treatment of mTNBC with TROP2-directed ADCs.

New trials reshape gastroesophageal adenocarcinoma care with durvalumab‑FLOT, HER2, and CLDN18.2 targets, plus practical toxicity tips.

A panel of experts gathered to discuss the landscape of care in early-relapse multiple myeloma, new phase 3 data, and select patient cases.

Experts discussed the evolving landscape of EGFR-mutated NSCLC, focusing on the practice-changing results of the ADAURA and NeoADAURA trials.

A panel of oncologists, pharmacists, and physician assistants discussed prevalent regimens for patients with recurrent endometrial cancer.

About 50% to 60% of Lambert-Eaton myasthenic syndrome cases occur secondary to a malignancy, most commonly small cell lung cancer, and 3% of patients with SCLC have LEMS.

Soft tissue sarcomas are a rare but heterogeneous group of tumors accounting for less than 1% of all cancers.

Learn SCAC risk factors, rising trends, and new frontline retifanlimab chemoimmunotherapy, plus PD‑1 options and emerging checkpoint strategies.

A panel of experts convened to explore the practical integration of BCMA-directed bispecific antibodies into clinical care for patients with multiple myeloma.

Read this discussion to spot LEMS red flags tied to small cell lung cancer, avoid misdiagnosis, and follow antibody/EMG testing and screening steps.

Discover how PSMA PET sharpens staging, guides radioligand therapy sequencing, and tackles real‑world access hurdles in advanced prostate cancer.

Learn how ctDNA monitoring predicts breast cancer recurrence and detects ESR1/PIK3CA resistance, enabling earlier, personalized therapy switches.

Peter Martin, MD, focused on the collaborative meeting setting and where the MCL research field is headed.

Kami Maddocks, MD, discusses how the push to define high-risk MCL for clinical trials was a focus at the 2025 MCL workshop.

Michael Wang, MD, discusses the impact of the MCL Scientific Consortium on the lymphoma community.

Results from arms C and D of the phase 3 SEQUOIA trial demonstrated that zanubrutinib alone or in combination with venetoclax yields positive results in CLL/SLL subpopulations.

C. Ola Landgren, MD, PhD, and Noopur Raje, MD, discussed results from the ADVANCE trial of DKRd in patients with newly diagnosed multiple myeloma.

A panel of experts gathered to discuss results from the MATTERHORN trial assessing durvalumab plus FLOT in gastric/GEJ cancer.

Expert teams debate cutting-edge lung cancer treatments, exploring trial data and innovative strategies for improving patient outcomes in NSCLC and SCLC.

Discover the latest breakthroughs in non-small cell lung cancer treatment from the 2025 WCLC, featuring competitive insights from leading experts.

Experts discussed how treatment should be sequenced for patients with small cell lung cancer who have brain metastases, highlighting recent clinical trial advancements and safety considerations.

Experts discuss the proper placement of Dato-DXd in the treatment of EGFR-mutated non–small cell lung cancer, comparing it with other potential treatments.

The latest advancements in bispecific antibodies and antibody-drug conjugates continue to improve the personalized treatment of advanced non-small cell lung cancer.

Explore the latest advancements in antibody-drug conjugates for treating metastatic triple-negative breast cancer and their unique safety profiles.

Experts at the 2025 IMS Annual Meeting discussed bispecific antibodies as treatment for multiple myeloma, highlighting various treatment strategies and real-world data insights.

Teclistamab shows promising real-world effectiveness for relapsed/refractory multiple myeloma, with high response rates and manageable safety profiles.

Oncology care requires psychosocial support, nutrition, and survivorship, which can result in improved patient outcomes and quality of life.

Explore the latest advancements in antibody-drug conjugates for treating metastatic triple-negative breast cancer, enhancing patient outcomes and safety.

Explore the promising role of antibody-drug conjugates targeting TROP2 in treating metastatic triple-negative breast cancer and improving patient outcomes.